While Argentina progressively advances with the plan from vaccination against the coronavirus, it was announced this Wednesday the realization of a study to find one new alternative from combination with the Sputnik V. The clinical trial will be done using the Russian drug and the chino from CanSino. Coordination will be in charge of the Guest Foundation, whose scientific director is the infectologist Pedro Cahn, one of the expert advisers of President Alberto Fernández.
“Fundación Huissa is coordinating a vaccine combination study between the first dose of Sputnik V and CanSino”, the institution begins by explaining in an official statement, and continues to summon “450 volunteers, over 18 years of age, who have received the first dose of the Sputnik V vaccine between the last 21 and 90 days and that they have not contracted COVID-19 at any time ”. The form can be accessed by clicking here.
In this sense, it was ensured that “all the people who participate in the study will receive a dose of the CanSino vaccine”, while “the immune response of the volunteers will be evaluated in four instances: at the beginning of the study, at 21 days, and at 3 months and 6 months after vaccination ”.
It was also explained that the CanSino substance, an “Ad5-nCoV vaccine”, is based “on a single-dose viral vector to prevent COVID-19 disease, which was jointly developed by the Beijing Institute of Biotechnology and CanSino Biologics. Inc. “. In this way, Host explains that “this study aims to increase the existing evidence on the combination of vaccines based on different platforms, thus helping to expand vaccination options against COVID-19.”
For his part, Cahn said: “This clinical trial is based on the fact that both the second dose of Sputnik V and Cansino use the adenovirus type 5 vector as a platform, that is, they share the same technology.”
“In addition, scientific evidence, the result of other vaccine combination studies that have been carried out in the world and in Argentina, has shown that there is a similar or even better efficacy with the combination of vaccines compared to vaccination with two doses of the vaccine. same vaccine ”, emphasized the scientific director of the Fundación Huiuda.